Antisense therapy for cancer

European Journal of Cancer, Supplement

Volumn 1, Issue 2, 2003, Pages 19-27

  Cotter, F E ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CGP 69846A; CHLORAMBUCIL; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLOPHOSPHAMIDE; DOXORUBICIN; G 3854; GENE EXPRESSION MODULATOR 231; ISIS 2503; ISIS 3521; MESSENGER RNA; OBLIMERSEN; PHOSPHOROTHIOIC ACID; PREDNISOLONE; PROCARBAZINE; PROTEIN BCL 2; PROTEIN KINASE C ALPHA; VINBLASTINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; B CELL LYMPHOMA; BINDING AFFINITY; BINDING SITE; BLOOD BRAIN BARRIER; CANCER SURVIVAL; CARCINOMA; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG SPECIFICITY; DRUG TARGETING; DRUG TISSUE LEVEL; DRUG TOLERABILITY; EOSINOPHILIA; GENE SILENCING; GENE TARGETING; HEMATOLOGIC DISEASE; HUMAN; HYPERGLYCEMIA; LEUKOPENIA; LYMPHOMA; MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; ONCOGENE C MYB; ONCOGENE H RAS; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PRURITUS; REVIEW; SLOW RELEASE FORMULATION; SWEATING; THROMBOCYTOPENIA;

EID: 2442509925     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6349(03)00011-9     Document Type: Article

References (28)

1. Lima W.F., Monia B.P., Ecker D.J., Freier S.M. Implication of RNA structure on antisense oligonucleotide hybridization kinetics. Biochemistry. 31:1992;12055-12061
2. Daaka Y., Wickstrom E. Target dependence of antisense oligodeoxynucleotide inhibition of c-H-ras p21 expression and focus formation in T24-transformed NIH3T3 cells. Oncogene Res. 5:1990;267-275
3. Bacon T., Wickstrom E. Walking along human c-myc mRNA with antisense oligodeoxynucleotides. maximum efficacy at the 5′ cap region Oncogene Res. 6:1991;13-19
4. Stein C., Cohen J. Phosphorothioate oligodeoxynucleotide analogues. Cohen J. Oligodeoxynucleotides: Antisense Inhibitors of Gene Expression. 1989;97-117 Macmillan, London
5. Cotter F., Johnson P., Hall P., et al. Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene. 9:1994;3049-3055
6. Agrawal S., Temsamani J., Tang J. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc. Natl. Acad. Sci. USA. 88:1991;7595-7599
7. Iversen P. In vivo studies with phosphorothioate oligonucleotides. pharmacokinetics prologue Anti-Cancer Drug Des. 6:1991;531-538
8. Raynaud F.I., Orr R.M., Goddard P.M., et al. Pharmacokinetics of G3139 a phosphorothioate oligodeoxynucleotide antisense to bcl-2 following intravenous administration or continuous subcutaneous infusion to mice. J Pharmacol Exp Ther. 281:1997;420-427
9. Cotter F.E., Corbo M., Raynaud F., et al. Bcl-2 antisense therapy in lymphoma. in vitro and in vivo mechanisms, efficacy, pharmacokinetics and toxicity studies Ann Oncol. 7(Suppl. 3):1996;32
10. Reed J., Cuddy M., Haldar S., et al. BCL2-mediated tumorigenicity of a human T-lymphoid cell line. synergy with MYC and inhibition by BCL2 antisense Proc. Natl. Acad. Sci. USA. 87:1990;3660-3664
11. Reed J., Stein C., Subasinghe C., et al. Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival. comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides Cancer Res. 50:1990;6565-6570
12. Pocock C., Malone M., Booth M., et al. BCL-2 expression by leukaemic blasts in a SCID mouse model of biphenotypic leukaemia model associated with the t(4;11)(q21;q23) translocation. Br. J. Haematol. 90:1995;867-885
13. Yamamoto S., Yamamoto T., Kataoka T., Kuramoto E., Yano O., Tokunaga T. Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN and augment IFN-mediated natural killer activity. J. Immunol. 148:1992;4072-4076
14. Hockenbery D., Nunez G., Milliman C., Schreiber R.D., Korsmeyer-S J. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 348:1990;334-336
15. Miyashita T., Reed J.C. bcl-2 Gene transfer increases relative resistance of S49. 1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res. 52:1992;5407-5411
16. Hermine O., Haioun C., Lepage E., et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de I'Adulte (GELA). Blood. 87:1996;265-272
17. Hill M.E., MacLennan K.A., Cunningham D.C., et al. Prognostic significance of Bcl-2 expression and Bcl-2 major breakpoint region rearrangement in diffuse large cell non- Hodgkin's lymphoma. a British National Lymphoma Investigation study Blood. 88:1996;1046-1051
18. Kramer M.H., Hermans J., Wijburg E., et al. Clinical relevance of BCL2, BCL6 and MYC rearrangements in diffuse large B-cell lymphomas. Blood. 92:1998;3152-3162
19. Macpherson N., Lesack D., Klasa R., et al. Small noncleaved, non-Burkitt's (Burkit-like) lymphoma. cytogenetics predicts outcome and reflect clinical presentation J Clin Oncol. 17:1999;1558-1567
20. Webb A., Cunningham D., Cotter F., et al. Effective human Bcl-2 antisense therapy in lymphoma. Lancet. 349:1997;1137-1141
21. Waters J.S., Webb A., Cunningham D., et al. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol. 18:2000;1812-1823
22. Bishop M.R., Iversen P.L., Bayever E., et al. Phase I trial of an antisense oligonucleotide OL(1) p53 in haematologic malignancies. J Clin Oncol. 14:1996;1320-1326
23. Selby P., Patel P., Milan-S, et al. ChlVPP combination chemotherapy for.Hodgkin's disease: long-term results. Br J Cancer. 62:1990;279-285
24. Stenn K.S., Lawrence L., Veis D., et al. Expression of the bcl-2 protooncogene in the cycling adult mouse hair follicle. J Invest Dermatol. 103:1994;107-111
25. Veis D.J., Sorenson C.M., Shutter J.R., Korsmeyer S.J. Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell. 75:1993;229-240
26. Kamada S., Shimono A., Shinto-Y, et al. Bcl-2 deficiency in mice leads to pleiotropic abnormalities: accelerated lymphoid cell death in thymus and spleen, polycystic kidney, hair hypopigmentation, and distorted small intestine. Cancer Res. 55:1995;354-359
27. Galbraith W.M., Hobson W.C., Giclas P.C., Schechter P.J., Agrawal S. Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res Dev. 4:1994;201-206
28. Park J.R., Bernstein I.D., Hockenbery D.M. Primitive human hematopoietic precursors express Bcl-x but not Bcl-2. Blood. 86:1995;868-876